Navixen (Eprosartan)

Eprosartan, the active ingredient in Navixen, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral administration. It selectively blocks the AT1 receptor, reducing vasoconstriction and aldosterone release, and is used to manage high blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Navixen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory conformity and reliable logistics for global healthcare providers. The company adheres to stringent manufacturing standards and provides comprehensive documentation for regulatory submissions.

Navixen (eprosartan) acts on the renin‑angiotensin‑aldosterone system to control blood pressure.

Hypertension: lowers systolic and diastolic pressure in patients with essential hypertension. Primary hypertension: provides sustained blood‑pressure reduction in adults with primary high‑blood‑pressure disease. Elevated blood pressure: assists clinicians in achieving target blood‑pressure goals in patients with persistently high readings.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity occurring during early treatment. - Fatigue: general tiredness without specific cause. - Nausea: occasional upset stomach or urge to vomit. - Abdominal discomfort: mild pain or cramping in the stomach area.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Hyperkalemia: elevated blood potassium levels that may cause cardiac rhythm disturbances. - Acute renal impairment: sudden decline in kidney function, especially in patients with pre‑existing renal disease. - Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury. - Severe hypotension: marked drop in blood pressure leading to fainting or shock.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor relevant parameters. - Renal function: assess serum creatinine and eGFR, adjust therapy if impairment is present. - Electrolytes: monitor potassium levels, especially when combined with potassium‑sparing agents. - Hepatic status: use caution in patients with severe liver disease. - Elderly patients: start at lower doses and observe for orthostatic symptoms. - Concomitant aliskiren in diabetes: avoid due to increased risk of renal complications. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Eprosartan may interact with several medicines; careful review is required. Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Dual blockade with ACE inhibitors or other ARBs: heightened risk of hypotension, renal impairment, and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous elevations in serum potassium. - Lithium: can raise lithium concentrations, leading to toxicity. - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood‑pressure lowering effect, monitor for excessive hypotension. - Other antihypertensives (beta‑blockers, calcium‑channel blockers): may require dose adjustments to avoid over‑lowering blood pressure. - CYP450 inhibitors (e.g., ketoconazole): may modestly increase eprosartan plasma levels, warranting observation.